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Abstract
Background: Rhabdomyosarcoma (RMS), one of the most common soft tissue sarcomas of childhood, is very rare
in the neonatal period (0.4–2% of cases). In order to gain a deeper understanding of this disease at such age,
patient and tumor features, as well as treatment modality and outcome need to be reported.
Case presentation: We describe two cases with congenital RMS treated at Bambino Gesù Children’s Hospital
between 2000 and 2016. They represent only 2.24% of all RMS patients diagnosed during that period in our
Institution; this data is in agreement with the incidence reported in the literature. They reflect the two different
clinical forms in which the disease may manifest itself. One patient, with the alveolar subtype (positive for specific
PAX3-FOXO1 fusion transcript) and disseminated disease, had a fatal outcome with central nervous system (CNS)
progression despite conventional and high dose chemotherapy. The other child, with the localized embryonal
subtype, was treated successfully with conservative surgery and conventional chemotherapy, including prolonged
maintenance therapy. He is disease free at 7 years of follow-up.
Conclusions: RMS can also be diagnosed during the neonatal period. Given the young age, disease management
is often challenging, and especially for the alveolar subtype, the outcome is dismal despite intensified multimodality
therapy. In fact, it characteristically manifests with multiple subcutaneous nodules and progression most commonly
occurs in the CNS (Rodriguez-Galindo et al., Cancer 92(6):1613–20, 2001). In this context, CNS prophylaxis could play
a role in preventing leptomeningeal dissemination, and molecular studies can allow a deeper tumor
characterization, treatment stratification and identification of new potential therapeutic targets.
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Background
Rhabdomyosarcoma (RMS) is one of the most common
soft tissue sarcomas of childhood. In 5–10% of cases, it
is diagnosed in children aged less than one year old, and
may be congential in 0.4–2% [1–3]. Various reports
indicate that, when the diagnosis occurs in the neonatal
period, the prognosis is worse than in older children
[2–7]. We retrospectively reviewed the medical records of
89 children affected by RMS treated between 2000 and
2016 at our Department and, among these, we found two
congenital cases. We report the clinical, radiological and
histological characteristics of these patients, as well as
therapeutic approach and outcome, together with a litera-
ture review of congenital RMS.
Case presentation
Case #1
A full term newborn girl presented with widespread
multiple nodular cutaneous and subcutaneous lesions on
the head, limbs and trunk. Her mother’s pregnancy as
well as family history were unremarkable. The color of
the lesions ranged from bluish to purple, a characteristic
of the so-called “blueberry muffin lesions”. She had no
dysmorphic features or congenital anomalies. Excisional
biopsy of one skin lesion showed a small-round-cell
tumor, with an alveolar pattern of growth consistent
with alveolar RMS (ARMS). Array-CGH analysis of
tumor cells detected the specific PAX3-FOXO1 fusion
transcript. Computed tomography (CT) revealed
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multiple lesions in the liver, pancreas, lungs, thoracic
and abdominal walls (Fig. 1). A magnetic resonance
image of the brain and spine showed a left retro-orbital
mass and a paravertebral lumbosacral lesion. Bone-
marrow and bones were positive for disease localization.
After disease staging no primary site could be detected
and the tumor was regarded as multifocal. The child was
classified as group IV according to the Intergroup
Rhabdomyosarcoma Study Group (IRSG) classification,
and as stage IV according to TNM pretreatment staging
classification [8]. She started chemotherapy with vincris-
tine, actinomycin-D and cyclophosphamide (age and
weight adapted doses). She presented a mixed response
after 4 courses: complete remission in bone-marrow,
skin and subcutaneous nodules; partial response of vis-
ceral, retro-orbital and lumbosacral lesions; leptomenin-
geal and pericardial progression. Following a discussion
with the family and their request for further treatment,
the child underwent chemotherapy with ifosfamide, vin-
cristine, actinomycin-D, doxorubicin and intrathecal
liposomial cytarabine arabinoside. The patient achieved
complete remission of leptomeningeal and pericardial
disease after 4 courses. Subsequently, she received high-
dose consolidation therapy with busulfan and melphalan
followed by autologous stem cell transplantation.
Unfortunately, after one month, she presented central
nervous system (CNS) recurrence and died of disease
progression at 9 months of age.
Case #2
A 5-day-old boy presented an abdominal mass in the
hypogastric region. His mother’s full-term pregnancy
was uncomplicated. Physical examination and routine
neonatal laboratory values were normal. Ultrasound of
the abdomen and pelvis showed a solid mass (greatest
diameter was > 5 cm) located between the posterior
bladder wall and sacrum. No family history of cancer
was reported. On the assumption that the lesion was of
benign nature, the child underwent macroscopically
complete surgical excision of the mass. Intraoperatively,
the tumor was found to originate from the prostate
gland. The pathological examination revealed an em-
bryonal RMS (ERMS). Molecular studies regarding
the tumour with real time polymerase chain reaction
(RT-PCR) did not reveal any PAX3-FOXO1 and
PAX7-FOXO1 fusion transcripts. The child was classified
as group II according to the IRSG classification and stage
III according to the TNM pretreatment staging classifica-
tion [8]. According to the European ongoing protocol
(NCT#00339118) for older children, he started
Fig. 1 a Axial contrast-enhanced CT image shows a multiple soft tissue masses in the subcutaneous fat with peripheral enhancement; some of
these masses expand in the muscles. In the left posterior part of the chest the mass can be seen to lie slightly lateral to the paravertebral region
(white arrow). b Axial, contrast-enhanced CT shows multiple low-density masses in the right and left lobes of the liver and in the pancreas. c Sagittal
T2-weighted MR imaging shows a lobulated, hyperintense presacral mass (white arrow). d Axial T2-weighted MR imaging shows heterogeneous
hyperintense intraorbital mass (white arrow)
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chemotherapy with 9 courses of vincristine, actinomycin-
D and ifosfamide (age and weight adapted doses). Due to
paralytic ileus, vincristine was reduced by 50% from the
third course onwards. Considering the young age, radio-
therapy was not delivered. Thus, it was decided to use a
prolonged maintenance therapy with 6 cycles of cyclo-
phosphamide and vinorelbine. He is disease free at 7 years
of follow-up and is doing well except for mild neurogenic
bladder dysfunction.
Discussion and conclusion
Congenital RMS is a very rare neoplasia, as confirmed
by data collected in our Institution over a 16-year
period: only 2.24% of all RMS patients were diag-
nosed with the congenital form. We also performed a
comprehensive PubMed search and 33 reports of con-
genital RMS (16 ERMS and 17 ARMS) published in
the last 30 years were found and reviewed (Table 1).
ERMS [9–22] ARMS [23–32]
The most frequent primary site for ARMS was the ex-
tremities, whereas for ERMS it was non-parameningeal
head and neck. The two cases we reported represent the
two different clinical forms in which the disease may
manifest itself. While congenital ERMS is often localized
and has the same behavior as that observed in older
children, congenital ARMS is a highly malignant tumor,
often occurring as a disseminated disease (see Case #1).
Moreover, ARMS often evolves with the development of
brain metastases despite an initial good response to
chemotherapy [23, 24]. For case #1, in order to obtain
CNS disease remission, we used intrathecal liposomial
cytarabine arabinoside, and given the well-known dismal
prognosis of the disease and the absence of other suit-
able alternatives, we decided to use consolidation high-
dose chemotherapy. However, the results with high-dose
chemotherapy reported in previous published trials, did
not show significant benefits in metastatic RMS [33, 34].
Currently, there are no specific guidelines regarding
treatment for neonates and infants with sarcoma, with
few exceptions, such as that of infantile fibrosarcoma
[35]. Infants with RMS are usually treated according to
the same protocols used for older children: mainly alkyl-
ating agents, vincristine, actinomycin-D, with or without
anthracyclines. However, they require tailored treat-
ments given the physiologic immaturity of various or-
gans. Ragab et al. [2] reported an unacceptable toxicity
compared with results in older children (5% versus 1%
of treatment-related deaths), when full chemotherapy
doses were used in infants treated in the IRSG I and II
trials. Chemotherapy dose reduction in infants resulted
in less fatal toxicities without affecting the overall out-
come [1, 3, 4]. Moreover, to avoid cardiac and renal
damage, anthracyclines and ifosfamide are omitted in
patients less than 3 and 1 months old respectively. With
regards to the management of congenital ARMS, we
hypothesized that children affected by this disease, could
benefit from early use of chemotherapeutic agents
with good blood-brain barrier passage as well as early
Table 1 Congenital Rhabdomyosarcoma: review of the literature
Patient and disease
characteristics
ERMS ptse
(n = 16)
ARMS ptse
(n = 17)
Gender: female/male
(sex ratio)
5/11 (0.45) 10/7 (1.4)
Primary site
PM head & neck – 1
Non PM head & neck 6 4
Orbit – –
GU non bladder-prostate 2 –
GU bladder-prostate 2 –
Extremities 1 7
Other site 5a 4b
NA – 1
IRSG
I 1 –
II 4 1
III 11 3
IV 1 13c
Molecular biology
Negative 2 5
NA 12 8
PAX3-FOXO1 positive – 3
PAX7-FOXO1 positive – –
Others 2 [t(2;8)] 1 [N-myc amplification]
Therapy
NA – 1
Surgery only 2 –
Chemotherapy only 2 9
Chemotherapy + surgery 9 4
Chemotherapy + surgery +
radiotherapy
3 2
Chemotherapy +
radiotherapy
– 1
Outcome
Alive [median months
from dg (range)]
8 [31.5 (6–240)] 4 [9 (6–240)]
Dead 2 13d
NA 6 –
ERMS embryonal rhabdomyosarcoma, ARMS alveolar rhabdomyosarcoma, pts.
patients, PM parameningeal, n number, GU genito-urinary, NA not available,
IRSG Intergroup Rhabdomyosarcoma Study Group, dg diagnosis
a2-perineal, 2-chest wall, 1-trunk
b2-trunk, 2-chest wall
cFor all patients, cutaneous and subcutaneous tissue was a metastatic site
d7/13 patients had central nervous system disease progression
eData about family history of cancer were not available
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intrathecal chemotherapy, as one of the main causes of
treatment failure is CNS progression. Local control, deter-
mined by extended surgery and radiotherapy, also poses
special challenges in very young children due to possible
sequelae. In the literature (Table 1), only 3 out of 16 pa-
tients with congenital ERMS received radiotherapy associ-
ated with conservative surgery (one of them was a female
with a vaginal primary who underwent brachytherapy)
[23]. Given the small number of patients and the lack of
follow-up data in about one third of cases (6\16), no con-
clusion can be drawn concerning the outcome. The Italian
Cooperative Group reported a higher local recurrence rate
in infants with RMS who did not receive appropriate local
treatment [1]. In our ERMS patient, since radiotherapy
was not recommended, we decided to prolong treatment
with maintenance chemotherapy. In this context, our de-
cision was taken in order to consolidate disease remission.
The potential role of maintenance therapy in this setting
is intriguing but impossible to define given the anecdotal
nature of our case. Few data are available regarding tumor
biology and fusion status, being reported in only 13 out of
33 cases (Table 1). Gene profiling, currently mandatory in
RMS, is even more important in congenital forms, which
present a challenging disease. In fact, it could allow more
accurate prognostic predictions, as well as detection of
new molecular targets. In this regard, molecular prognos-
tic factors have already been identified for a subgroup of
congenital RMS, namely the spindle-cell type [36]; the
tumors carrying NCOA2 gene rearrangements indeed
showed a more favorable clinical course.
In conclusion, although rarely, RMS can also arise in
the neonatal period. In these patients, it is often difficult
to establish a balance between the necessity to cure and
the risk of long-term effects. A large effort to elaborate
guidelines/protocols is desirable to homogenize treat-
ment for this rare tumor occurring within this age
group. From experience gathered in the 2 reported cases,
early CNS prophylaxis should be considered for the
alveolar subtype and prolonged maintenance chemother-
apy rather than radiotherapy might be envisaged for the
localized embryonal type. Moreover, deeper molecular
biology studies are crucial for tumor characterization,
treatment stratification and for the discovery of new
therapeutic targets.
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